In Silico analysis identification of long noncoding RNAs associated with genes involved in response to trastuzumab antibody treatment in gastric cancer cells using microarray data

Backgrounds: Gastric cancer, the fourth most common cancer worldwide and the secondleading cause of cancer death was known as a heterogeneous, multifactorial, highly malignanttype of cancer. Long noncoding RNA (LncRNA) is functional RNA, longer than ۲۰۰ nucleotideswithout the potential for coding protein. Like protein-coding genes, lncRNAs are regulated bytranscription factors and other regulators. Therefore, by discovering LncRNAs associated withgenes involved in the therapeutic response to trastuzumab, further experiments can be performedto identify pathways that lead to drug resistance, especially trastuzumab, as possible goals ofinhibiting relapse.Materials and Methods: Using the GEO database and analyzing the expression profiles ofgenes of gastric cancer patients (cells N۸۷-TR۱, N۸۷-TR۲, N۸۷-TR۳, N۸۷-TR۴, NCI-N۸۷) whoreceived trastuzumab (Datasets GSE۷۷۳۴۶ and Illumina HumanHT platform), genes wereexamined. Then, five more significantly different genes were identified and LncRNAs associatedwith genes involved in the therapeutic response to trastuzumab were identified through theLncRNA۲Target v۲.۰ database.Results: Based on the analysis of GEO۲R software and using LncRNA۲Target v۲.۰ database,five LncRNAs were identified that were associated with genes involved in the therapeuticresponse to trastuzumab, including: (KLK۶ = HOXC-AS۳, TACSTD۲ = NBAT۱, KRT۱۹ =NBAT۱, ADGRG۱ = ACOO۷۱۲۸.۱, MSLN = HOXC-AS۳).Conclusion: Considering the identification of two common LncRNAs between ۴ different genes,it can be said that NBAT۱ and HOXC-AS۳ are two of the main LncRNAs when treated withtrastuzumab for therapeutic response in patients with GC. Therefore, with further testing, theidentified LncRNAs, including ACOO۷۱۲۸.۱ and especially HOXC-AS۳, NBAT۱, can bementioned as possible targets for inhibiting GC recurrence.

کلیدواژه ها:

Long noncoding RNAs ، Gastric cancer ، Trastuzumab antibody